Multiple pharmaceutical companies on the STAR Market disclose R&D progress and major transaction developments simultaneously

On the evening of March 4th, five biotech and pharmaceutical companies listed on the STAR Market—Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “Shengnuo Bio”), Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. (hereinafter referred to as “Sunshine Nuohe”), Jiangsu Kangwei Century Biotechnology Co., Ltd. (hereinafter referred to as “Kangwei Century”), Shanghai Sanyou Medical Devices Co., Ltd. (hereinafter referred to as “Sanyou Medical”), and Shouyao Holdings (Beijing) Co., Ltd. (hereinafter referred to as “Shouyao Holdings”)—disclosed their research and development progress and major transaction updates.

Shengnuo Bio announced that its controlling subsidiary recently received the “Approval Notice for the Listing of Raw Material Linaclotide” issued by the National Medical Products Administration (NMPA). This drug is mainly used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), and is the first medication with this mechanism of action for treating constipation.

Sunshine Nuohe announced that it and its subsidiaries received the “Drug Clinical Trial Approval Notice” from the NMPA. The clinical trial application for its project BTP4327 has been approved, and the drug is intended for monotherapy in patients whose blood pressure cannot be sufficiently controlled.

Kangwei Century announced that its wholly owned subsidiary’s nine nucleic acid test kits for respiratory pathogens (fluorescent PCR method) received a Class III “Medical Device Registration Certificate (In Vitro Diagnostic Reagents)” issued by the NMPA.

Sanyou Medical announced that its SWINGO-3D Lumbar Cage System (3D-printed lumbar interbody fusion system) received FDA 510(k) certification, designed for use in conjunction with auxiliary internal fixation systems.

Shouyao Holdings disclosed an adjustment to its collaborative R&D model for a new anti-tumor drug class JAK2 inhibitors. After the adjustment, in addition to the original milestone income of 3 million RMB stipulated in the agreement, Chia Tai Tianqing will also make a one-time payment of 80 million RMB in two installments as a lump sum benefit to the company.